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Angiopoietin-like protein 2 (Angptl2) is a secreted glycoprotein that has been implicated in angiogenesis, inflammation
and atherosclerosis as well as enhancing the survival of human hematopoietic stem cells. Glycosylation of Angptl2 is
required for biological activity and studies of angiopoietin-like protein 2 have been hindered by the lack of a source for
the mature form of this protein. We describe a system that permits purification of the glycosylated form of human
Angptl2 from conditioned media of stably transfected HEK 293 cells. To facilitate purification while retaining the
integrity of Angptl2’s endogenous N-terminal secretion signal peptide, GST was fused downstream of the Angptl2
coding sequence. Secreted Angptl2-GST was purified using a one-step glutathione-affinity purification scheme. The
purity and identity of the resulting protein were confirmed by SDS-PAGE, immunoblotting, and mass spectrometry.
N-Glycosidase treatment reduced the apparent molecular mass of Angptl2-GST on SDS-PAGE, confirming its
glycosylation state. Purified human Angptl2-GST stimulated both HUVEC migration and microtubule formation
in vitro. The yield of Angptl2-GST obtained was in quantities suitable for multiple applications including functional
in vitro and in vivo assays.
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Angiopoietin like-2 (Angptl2) is a widely expressed, 57-kDa
protein secreted into the circulation (Kim et al. 1999).
Angptl2 is expressed in the heart, adipose tissue, stomach,
small intestine, colon, ovary, uterus, spleen, striated muscle,
and, at lower levels, in other tissues (Kim et al. 1999; Tabata
et al. 2009) and Angptl2 is secreted by different cell types
such as adipocytes (Tabata et al. 2009), endothelial cells
(Farhat et al. 2013), macrophages (Tazume et al. 2012), ker-
atinocytes (Ogata et al. 2012) and cancer cells (Endo et al.
2012). The primary structure of Angptl2 predicts an N-
terminal coiled-coil domain, a C-terminal fibrinogen-like
domain, as well as 2 sequential consensus sites for po-
tential N-glycosylation and a hydrophobic region at the
N-terminus typical of a secretory signal sequence (Kim
et al. 1999). The coiled-coil domain appears to be suffi-
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in any medium, provided the original work is pproliferation (Zhang et al. 2006; Broxmeyer et al. 2012). In
contrast, alignment of the 7 angiopoietin-like proteins sug-
gests that the fibrinogen-like domain is required for their
angiogenic activities (Hato et al. 2008) and the fibrinogen-
like domain of Angptl3 is sufficient to induce angiogenesis
(Camenisch et al. 2002). Hence, Angptl2 may function as
at least a bifunctional ligand in terms of its effects upon
different target cell populations.
Although the Angptl2 receptor remains to be identi-
fied, a recent study identified the immune-inhibitory
receptor human leukocyte immunoglobulin-like receptor B2
(LILRB2) and its mouse ortholog, paired immunoglobulin-
like receptor (PIRB), as receptors for angiopoietin like-2, −5
and −7 in hematopoietic stem cells (Zheng et al. 2012).
Recent findings report strong evidence that Angptl2 medi-
ates chronic inflammation (Tabata et al. 2009; Endo et al.
2012; Ogata et al. 2012; Tazume et al. 2012; Farhat et al.
2013), making Angptl2 a potential therapeutic target, but
there are currently no inhibitors or antagonists available
to facilitate studies of the intracellular signaling pathways
activated by Angptl2. Furthermore, although mamma-
lian cell-expressed Angptl2 increased hematopoietic stemn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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suggesting mammalian-specific post-translational modifi-
cation, likely glycosylation, of Angptl2 that contributes
to, or is required for, one or more of its physiological func-
tions (Zhang et al. 2006). Full length Angptl2 having mam-
malian cell-type glycosylation is not currently commercially
available, which is an impediment to the further study of
the physiological function and down stream signaling of
Angptl2. Although some studies report the use of recom-
binant glycosylated Angptl2 protein, there are almost no
methodological details concerning its preparation and puri-
fication (Zhang et al. 2006; Akhter et al. 2013; Farhat et al.
2013). Our objective was therefore to describe the cloning,
expression, and purification of the mature glycosylated
form of human Angptl2 as a GST fusion protein, Angptl2-
GST. Purified, recombinant Angptl2-GST retains its ex-
pected pro-angiogenic and chemotactic effects on cultured
HUVEC cells, indicating it is able to bind and activate its
cognate receptor, suggesting that it is suitable for multiple
applications including functional in vitro and in vivo assays.
Results and Discussion
Expression and purification of recombinant Angptl2-GST
Angiopoietin-like protein 2 is a glycoprotein that is
expressed in many tissues (Kim et al. 1999). Bacterially
expressed Angptl2 is unable to stimulation expansion of
hematopoietic stem cells, indicating that appropriate post-
translational modification is required for Angptl2 to be
functional (Zhang et al. 2006). To this end, a line of stably
transfected HEK 293 cells expressing human Angptl2
as a GST-fusion protein (Angptl2-GST) was created. Briefly,
the full-length cDNA for human Angptl2 was obtained
from OpenBioSystems in a pSPORT1 vector (clone ID
LIFESEQ2268890; Figure 1A) and subcloned into pcDNA3.1
as described in METHODS and summarized in Figure 1.
The resulting construct comprised the full-length Angptl2
coding sequence followed by GST (pcDNA3.1-Angptl2-
GST; Figure 1D). pcDNA3.1-Angptl2-GST was trans-
formed into E. coli DH5α competent cells, amplified, puri-
fied, and verified by sequencing.
Following sequence validation, HEK 293 cells were trans-
fected with pcDNA3.1-Angptl2-GST. Twenty-four h after
transfection, the media was replaced with fresh DMEM
supplemented with 1 mg/ml G418 and HEK 293 cells
were cultured in the presence of G418 to select for stably
transfected cells expressing Angptl2-GST. Once a stable
line was obtained, their ability to express and secrete
Angptl2-GST was assessed. Angptl2-GST was purified
from conditioned media using glutathione affinity chro-
matography on 1 ml GSTrap FF columns (GE Healthcare;
Figure 2). The elution of Angptl2-GST from glutathione
Sepharose was assessed by separating an aliquot of each
fraction on SDS-PAGE and visualizing the proteins
using Coomassie Brilliant Blue R250 (Figure 2A). Theidentity of the protein eluting from glutathione Sepharose
as Angptl2-GST was confirmed by immunoblotting using
an Angptl2-specific antibody (Figure 2B). Purified recom-
binant Angptl2-GST migrated on SDS-PAGE with an
observed molecular mass of ~90 kDa (Figure 2C), which
corresponds with that predicted for Angptl2 (64-kDa) plus
GST (28-kDa). The identity of this band as Angptl2-GST
was further confirmed by tandem MS/MS.
Tandem MS/MS verification of expressed human
angiopoietin-like protein 2. To confirm the expressed,
purified protein was human angiopoietin-like protein 2,
the 90-kDa band revealed by Coomassie staining was ex-
cised and submitted to the IRIC Proteomics Core facility
for sequencing by LC-MS/MS (http://www.iric.ca/en/
research/core-facilities/proteomics/). The unique pep-
tides identified by MS are in bold in the sequence shown
below. Similar results were obtained following analysis
performed in 3 separate preparations of human
Angptl2. In total, 12 unique peptides were identified,
representing 88 out of a total of 493 amino acids and
hence 17.8% sequence coverage.
1 mrplcvtcww lgllaamgav agqedgfegt eegsprefiy
lnrykrages qdkctytfiv
61 pqqrvtgaic vnskepevll enrvhkqele llnnellkqk
rqietlqqlv evdggivsev
121 kllrkesrnm nsrvtqlymq llheiirkrd nalelsqlen
rilnqtadml qlaskykdle
181 hkyqhlatla hnqseiiaql eehcqrvpsa rpvpqpppaa
pprvyqppty nriinqistn
241 eiqsdqnlkv lppplptmpt ltslpsstdk psgpwrdclq
aledghdtss iylvkpentn
301 rlmqvwcdqr hdpggwtviq rrldgsvnff rnwetykqgf
gnidgeywlg leniywltnq
361 gnykllvtme dwsgrkvfae yasfrlepes eyyklrlgry
hgnagdsftw hngkqfttld
421 rdhdvytgnc ahyqkggwwy nacahsnlng vwyrgghyrs
ryqdgvywae frggsyslkk
481 vvmmirpnpn tfh
The yield of this expression system ranged from 25 to
100 μg of pure human Angptl2-GST per liter of condi-
tioned media loaded onto the GSTrap columns. Digitizing
the Coomassie-stained gels and assessing protein purity
using Quantity One software (Bio-Rad Laboratories, Inc.)
revealed the purity of Angptl2-GST to be > 95%. Each
purification comprised 2–2.5 liters of conditioned media,
which represented 6 weeks of cell culture. The number of
flasks maintained in culture was adjusted so that the col-
umns were loading continuously, via a 150 ml Superloop,
at 0.2 ml/min. Higher flow rates were not sustainable over
the long term, as the column bed compacted and back
pressure increased beyond the limit of the GSTrap col-
umns (0.3 MPa). Although the conditioned media was
Figure 1 Strategy for constructing human Angptl2-GST. A) Map of the SPORT1-hAngptl2 vector obtained from OpenBioSystems. B) PCR
amplification of a fragment corresponding to the 3’ region of Angptl2 without the stop codon and subcloning it into the pcDNA3.1 vector.
C) Creating a fusion constructs containing the 3’ fragment of Angptl2 plus GST. D) Full-length Angptl2-GST construct (solid arrow) indicating the
fragments used in its assembly (open arrows).
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the columns were further protected by placing an in-line
filter between the Superloop and the column. All buffers
were filtered to 0.2 μm. Furthermore, the entire FPLC
system was maintained at 5°C in a refrigerated chro-
matography cabinet. As Angptl2-GST has been shown
to be pro-inflammatory, the endotoxin content was ex-
amined and found to be less than 1 endotoxin unit (EU)
per microgram of purified Angptl2-GST. This value is
comparable to full-length recombinant Angptl2 purified
from E coli or truncated recombinant Angptl2 purified from
human cell expression systems currently available from
commercial sources.Purified Angptl2-GST is glycosylated
Endogenous Angptl2 is glycosylated and posttranslational
modification of Angptl2 appears to be required for it to be
functionally active with respect to regulating the activities
of the target cell (Zhang et al. 2006). Kim and coworkers
have previously shown that post translation modifica-
tion increases the apparent molecular weight of Angptl2-
GST on SDS-PAGE from 57-kDa to greater than 64-kDa
(Kim et al. 1999). SDS-PAGE resolved purified Angptl2-
GST into 3 bands (Figure 3), which likely correspond
to different posttranslationally modified states of Angptl2.
To confirm the glycosylation state of purified recombin-































Figure 2 Purification of recombinant human Angptl2-GST from conditioned media. After loading the GSTrap column with 2–2.5 liters of
conditioned media, the column was washed with TBSE and then eluted with 10 mM glutathione in TBSE. The fractions obtained during the
elution of Angptl2-GST from the GSTrap column were resolved on SDS-PAGE to assess the specificity of the purification. A) Following SDS-PAGE,
proteins were detected by staining with Coomassie Brilliant Blue. Lane 1 of each gel contains molecular mass markers. Lanes 2–10 contain the
indicated fraction number (5 μl each). B) Immunoblotting of the GSTrap elution profile. The samples loaded were 0.1 μl of the same fractions in
panel A, loaded on a separate set of 10% acrylamide gels and Immunoblotted as described in Methods. The membranes were probed using an
antibody specific for human Angptl2 antibody. C) Quantification of purified Angptl2-GST. An aliquot (2 μl) of purified Angptl2-GST was resolved
on SDS-PAGE (10% acrylamide) along with a standard curve of BSA (0.1, 0.2, 0.3, 0.5, 1 and 2 μg). The gels were stained with Coomassie Brilliant
Blue R-250, digitized using a two-dimensional gel scanner, and band intensities for BSA and Angptl2-GST determined using Quantity One software
and the quantity of Angptl2-GST determined from a linear regression analysis of a plot of band intensity versus micrograms of BSA loaded using
GraphPad Prism software.
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an amidase that cleaves between the GlcNAc and aspara-
gine residues of N-linked glycoproteins, thus removing
both high mannose and complex glycosylations. Following
digestion of Angptl2-GST with PNGase F, only a single
band of 57-kDa was observed (Figure 3), having an
apparent molecular mass similar to commercially available,
inactive, recombinant GST-Angptl2 (Novus Biologicals).
Thus, like endogenous Angptl2, recombinant Angptl2-GST
purified from media conditioned by stably transfected
HEK 293 cells is also N-glycosylated.Functional assays of purified recombinant Angptl2-GST
Several studies have shown that Angptl2 is pro-angiogenic:
it stimulates the formation of new blood vessels in the
Zebra fish (Kubota et al. 2005) and has been implicated in
the maturation of blood vessel and the formation of arter-
ies (Tabata et al. 2009). In addition, Angptl2 stimulates
HUVECs to form tube-like structures (Kim et al. 1999).
Studies have also shown that Angptl2 serves as a chem-
ical attractant, stimulating the migration of monocytes/
macrophages in culture (Tabata et al. 2009) and in the
native endothelium (Farhat et al. 2013). To determine if
Figure 3 Deglycosylation of Angptl2-GST. Purified Angptl2-GST
was incubated with in the absence (Lane A) or presence of PNGase F
(Lane B) at 37°C for 5 h and then, along with commercially available
human GST-Angptl2 (Novus Biologicals; Catalog number
H00023452-P01; Lane C), resolved on SDS-PAGE (10% acrylamide),
transferred to nitrocellulose (0.2 μm), and then visualized by
immunoblot analysis using an Angptl2-specific antibody.
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the chemotactic and pro-angiogenic effects of native
Angptl2, we assessed both of these properties in vitro. To
examine the effects of Angptl2-GST on endothelial cell
migration, HUVECs were plated in the upper chamber of
transwell inserts and cultured in the presence of vehicle,
Angptl2-GST, or VEGF in the lower chamber. Figure 4
shows Angptl2-GST increased the migration of HUVEC
across the insert (from 25 ± 5 to 82 ± 10 cells/field, p <Control Angptl2-
Figure 4 Angptl2-GST promotes endothelial cell migration. Upper Pan
across the polycarbonate membranes (porosity 5 μm) separating the cham
(Control), supplemented with 1 nM Angptl2-GST or 25 nM VEGF. Lower Pa
membrane. For each experiment, conditions were assayed in duplicate and
are mean ± SEM; n = 4; *, p < 0.05 versus control.0.05) to a similar extent as that observed with VEGF (from
25 ± 5 to 115 ± 26 cells/field, p < 0.05). Microtubule forma-
tion is an indicator of angiogenesis. Hence, to determine if
Angptl2-GST is able to promote microtubule formation,
HUVECs were seeded onto Matrigel-coated plates and
stimulated with vehicle, Angptl2-GST, or VEGF for 48 h.
Angptl2-GST increased microtubule formation (from 22 ±
7 to 67 ± 9 AU, p < 0.05) to a similar extent as did VEGF
(from 22 ± 7 to 72 ± 10 AU, p < 0.05) (Figure 5). Taken
together, these results confirm that Angptl2-GST is
functional in that it promotes microtubule formation
and chemotaxis as shown previously for the endogenous
Angptl2. Thus the recombinant human Angptl2-GST ob-
tained as described herein can be used to study the physio-
logical and pathological roles of Angptl2, and we recently
reported that Angptl2-GST is highly pro-inflammatory
and induces atherogenesis in mice when injected in vivo
(Farhat et al. 2013).
Studies characterizing the biological versus pathological
function of a protein often include an examination of
effects evoked by addition of the protein of interest. In the
case of Angptl2 such studies are difficult due the lack of
commercial availability of the protein. To date, commercial
sources provide the full-length recombinant form of
Angptl2. These sources use transgenic plant cells or E coliGST VEGF
els) Phase contrast images showing HUVECs that have migrated
bers in the transwells under the following conditions: culture media
nel) Histogram showing the number of cells having migrated across
5 randomly chosen fields were quantified per condition. Data shown
Control Angptl2-GST VEGF
Figure 5 Angptl2-GST promotes the formation of tubules in cultured HUVEC cells. Upper Panels) The effect of Angptl2-GST on the ability
of HUVECs to form a tubular network was assessed using an inverted microscope (400 ×). HUVECs were cultured on Matrigel-coated plates (on 6-well
plates) for 24 h at 37°C and then stimulated, or not (control), for an additional 48 h with 1 nM Angptl2-GST or 25 nM de VEGF. Lower Panel) Histogram
showing the number of adhesion points between microtubules. For each experiment, conditions were assayed in duplicate and 5 randomly chosen
fields were quantified per condition. Data shown are mean ± SEM; n = 4; *, p < 0.05 versus control.
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sive means of expressing large amounts of the protein.
However, these expression systems are unable to catalyze
the pattern of glycosylation characteristic of eukaryotic
glycoproteins (Ma et al. 2003). In order to express a func-
tional recombinant form of Angptl2, it is essential to use a
mammalian cell system. Due to the presence of an N-
terminal signal sequence, the expressed Angptl2 is proc-
essed by the ER-Golgi system and secreted constitutively
into the culture medium. By including a C-terminal GST
moiety, we were able to employ a single-step protocol for
the enrichment and purification of Angptl2-GST from
conditioned media using GSTrap columns coupled with
an FPLC system. The major drawback to such a system is
the relatively low recovery of Angptl2, but this is circum-
vented by the fact that the concentration of Angptl2-GST
needed to obtain a functional effect is in the order of nM.
To the best of our knowledge, this is the first full descrip-
tion of the cloning, expression and purification of a ma-
ture glycosylated form of recombinant Angptl2.
Conclusions
Angiopoietin-like protein 2 is a glycoprotein that is se-
creted by numerous cell types and has been shown to
promote angiogenesis, inflammation and atherosclerosis
as well as the survival of human hematopoietic stem cells.We have developed a protocol to express and purify hu-
man Angptl2-GST. A line of stably transfected HEK 293
cells was employed, as a mammalian cell system provides
for the appropriate posttranslational modification of the
recombinant protein. Subsequent analysis confirmed that
the purified recombinant protein was glycosylated and
retained the ability to promote endothelial cell migration
and microtubule formation as reported previously for the
endogenous Angptl2. Hence, our method of preparing
purified recombinant human Angptl2-GST can be used to
study the role of this protein both in vivo and in vitro.
Methods
Construction of a recombinant pcDNA-Angptl2-GST
expression plasmid
Subcloning the 3’ of Angptl2 into pcDNA3.1
The full-length cDNA for human Angptl2 was obtained
from Open Biosystems (pSPORT1-Angptl2; clone ID
LIFESEQ2268890) (Figure 1A). A 3’ fragment of Angptl2,
corresponding to nucleotides 1065–1479, was PCR amp-
lified from pSPORT1-Angptl2 using primers that ex-
cluded the stop codon and added specific restriction
cloning sites at the 3’ and 5’ ends. More specifically, the
primers were designed as follows: 1) The ‘sense’ primer
comprised sequence upstream of the BstEII site plus re-
striction sites specific for EcoRI and AgeI (Table 1);
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3’ sequence of Angptl2, excluding the stop codon, plus
EcoNI (in phase with the Angptl2 coding sequence) and
Xho1 sites (Table 1; underline). A fragment corresponding
to the 3’ region of the Angptl2 coding sequence was amp-
lified by PCR using Elongase and Elongase Enzyme Mix
(Invitrogen) according to the manufacturer’s instructions.
Briefly, 1 μl of plasmid DNA was combined with 1 μl of
10 mM dNTP, 1 μl each of sense and antisense primers
(1 mM stock), 8 μl buffer A (5× stock comprising 300 mM
Tris-SO4 (pH 9.1 at 25°C), 90 mM (NH4)2SO4, and 5 mM
MgSO4], 2 μl buffer B [5× stock comprising 300 mM Tris-
SO4 (pH 9.1 at 25°C), 90 mM (NH4)2SO4 and 10 mM
MgSO4] and the final reaction volume adjusted to 50 μl
with DNase-free H2O. Plasmid DNA was denatured at
94°C for 30 s and amplified for 30 cycles as follows: 30 s
at 94°C (denaturation) followed by 30 s at 55°C and finally
45–60 sec at 68°C (elongation). The resulting 449 bp PCR
product was resolved on a 2% agarose gel, the band ex-
cised, and the DNA extracted from the gel using a Gel
Extraction Kit (Qiagen) (Figure 1B). To insert the 3’
Angptl2 cDNA fragment into the pcDNA3.1 neo (+) plas-
mid (Invitrogen), it was first necessary to modify the
ends of the insert to be compatible with the vector.
To accomplish this, vector and purified PCR product
were digested with EcoRI. The EcoRI was then inacti-
vated (70°C, 20 min) and a second digestion performed
using XhoI. Between the first and second digestions, the
EcoR1 buffer was removed by centrifugal filtration (Micro-
con YM-30 centrifugal filters, Millipore) and replaced with
a buffer appropriate for EcoNI. The digested insert and
vector were gel-purified and then ligated. The resulting
pcDNA3.1-3’Angptl2 plasmid was transformed into com-
petent DH5α cells, amplified, extracted and purified using
MiniPrep kits. The presence and integrity of the insert was
confirmed by digestion with EcoRI/EcoNI followed by
agarose gel electrophoresis and sequencing.
The primers employed in the cloning of human
angiopoietin-like protein 2 were designed to create 4
novel restriction sites. The nuleotides comprising each
site are underlined and in italics with the endonucle-
ase indentified immediately below.
Introducing GST cDNA
To preserve the functional integrity of the secretion signal






Angptl2’_ASinserted 3’ to Angptl2. The glutathione S transferase (GST)
coding region was excised from the pGEX-6P-2 vector
(Amersham) by digestion with XhoI (3’) followed by EcoNI
(5’) and then purified on a 2% agarose gel. The pcDNA3.1-
3’Angptl2 (nucleotides 1065–1479) plasmid was similarly
digested with XhoI followed by EcoNI and the GST frag-
ment was inserted in-frame 3’ to the Angptl2 coding re-
gion (Figure 1C). The product, pcDNA3.1-3’Angptl2-GST,
was then transformed into competent bacteria, amplified,
purified, and the integrity of the insert determined by se-
quencing as described above.Assembly of full-length Angptl2
A fragment of Angptl2 comprising nucleotides −304
to +1098 was excised from the pSPORT1-Angptl2 vector
(clone ID LIFESEQ2268890) by digestion with AgeI and
BstEII (Figure 1D) and then inserted into the pcDNA3.1-
3’Angptl2-GST plasmid, also digested with AgeI and BstEII,
resulting in reconstitution of the full-length Angptl2 coding
sequence. pcDNA3.1-Angptl2-GST was transformed into
E. coli DH5α competent cells, amplified, purified, and veri-
fied by sequencing.Stable expression of recombinant human Angptl2-GST in
HEK293 cells
As Angptl2 is a glycoprotein (Kim et al. 1999), a eukaryotic
expression system was employed to insure that the
expressed protein underwent appropriate posttranslational
modification. Low passage number HEK 293 cells were ob-
tained directly from Invitrogen and maintained in DMEM
containing 10% de FBS and 1% penicillin/streptomycin.
HEK 293 cells were transfected with pcDNA3.1-Angptl2-
GST using Lipofectamine 2000 (Qiagen). Twenty-four h
after transfection, the media was replaced with fresh
DMEM supplemented with 1 mg/ml G418. Once a stable
cell line was established, the ability of the cells to secrete
intact Angptl2-GST into the culture medium was verified
by immunoblotting (Figure 2). Cells were washed twice
with PBS and then cultured in serum-free DMEM. Forty
eight hours later the media was recovered, centrifuged
for 30 min at 13,000 rpm and 4°C, and 1 ml of the super-
natant concentrated 50-fold using centrifugal filtration
units (Amicon Ultra-0.5 ml; 10 kDa nominal molecular
weight limit). To minimize the potential for product
loss due to non-specific protein binding, the filter unit
was blocked using 10% FBS in DMEM (30 min, 5000 × g,
4°C). The concentrated, conditioned media was then sepa-
rated on 12.5% acrylamide SDS-PAGE, transferred to
nitrocellulose, blocked, and probed using a goat Angptl2-
specific antibody (R&D) diluted 1:200 in TBST containing
5% skim milk (Carnation).
Upon confirmation of a stable cell line secreting full-
length Angptl2-GST, cells were aliquoted, suspended in
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and stored under liquid nitrogen.Purification of Angptl2-GST
Stably transfected HEK 293 cells expressing Angptl2-GST
were cultured in 175 cm2 flasks and the conditioned
media harvested every 2–3 days, centrifuged for 2 h at
40,000 rpm and 4°C (Beckman Type 45 Ti rotor) to re-
move dead cells and debris, and applied to 1 ml GSTrap
columns at 0.2 ml/min, using an FPLC maintained at
5°C. Columns were equilibrated with buffer comprising
50 mM Tris–HCl, 150 mM NaCl, 1 mM EDTA, pH 7.5 at
5°C (TBSE). For each preparation of Angptl2-GST, 2–2.5
liters of conditioned media was applied to the columns.
The columns were then washed with 10 ml TBSE and
eluted with TBSE containing 10 mM reduced glutathione
(pH 8.0 at 4°C). Twenty fractions of 0.5 ml were collected.
To determine the elution and purity of Angptl2-GST, ali-
quots of each fraction were subjected to both SDS-PAGE
and immunoblotting. A 5-μl aliquot of each fraction was
resolved on 10% acrylamide SDS-PAGE and the pro-
teins revealed using Coomassie Brilliant Blue R250. In
addition, 0.1 μl was resolved on 12.5% acrylamide SDS-
PAGE, transferred to nitrocellulose, and revealed using
Angptl2-specific antisera (Figure 2B). Once identified, the
fractions containing Angptl2-GST were pooled, concen-
trated by centrifugal filtration (Amicon Ultra-0.5 ml;
nominal molecular weight cut-off 10-kDa), and dialyzed
against TBSE (4 buffer changes, 1000-fold buffer volume,
10-kDa NMWT cut-off Spectra/Por dialysis membranes)
at 4°C. The final concentration of Angptl2-GST in each
preparation was determined by separating both Angptl2-
GST and a standard curve of BSA (0.1, 0.2, 0.3, 0.5, 1 and
2 μg; Figure 2C) on SDS-PAGE.
The gels were stained with Coomassie Brilliant Blue
R-250, digitized using a two-dimensional gel scanner,
and band intensities for BSA and Angptl2-GST deter-
mined using Quantity One software (Bio-Rad Laborator-
ies). The mass of Angptl2-GST was determined by linear
regression analysis of a plot of band intensity versus mi-
crograms of protein (GraphPad Prism Version 4.00 for
Mac).SDS-PAGE Analysis
Proteins were denatured by heating for 5 min at 80°C in
Laemmli sample buffer (final concentrations: 50 mM
Tris–HCl pH 6.8, 0.5 M β-mercaptoethanol, 2.5% SDS,
0.4 M sucrose, 1 mM EDTA and 0.05% bromophenol
blue) and separated on 10% acrylamide SDS-PAGE
mini-gels for 90 min at 100 V. To reveal proteins, gels
were stained in 45% (v/v) denatured ethanol, 10% (v/v)
acetic acid containing 0.1% (w/v) Coomassie brilliant
blue R-250 and destained in 20% (v/v) denatured ethanolcontaining 10% (v/v) acetic acid. Bands were quantified
using Quantity One software (Bio-Rad Laboratories).
Immunoblot Analysis
Following SDS-PAGE, proteins were transferred to nitrocel-
lulose membranes for 90 min at 100 V and 4°C in transfer
buffer (25 mM Tris base, 192 mM glycine, 5% methanol).
Membranes were blocked for 2 h at room temperature
using 5% fat-free milk in 25 mM Tris–HCl pH 7.5, 150 mM
NaCl, 0.05% (v/v) Tween 20 (TBST). To detect Angptl2
immunoreactivity, membranes were incubated for 3 h
at room temperature with a goat anti-Angptl2 antibody
(R&D Systems Catalog #AF2084) diluted 1:200 in blocking
buffer. After washing 3 times (10 min each) in TBST, mem-
branes were incubated for 2 h with horseradish peroxidase-
conjugated donkey anti-goat secondary antibody (Jackson
ImmunoResearch Laboratories) diluted 1:10,000 in block-
ing buffer. Finally, after 3 additional 10 min washes
in TBST, immunoreactive bands were revealed by chemilu-
minescence (PerkinElmer) using BioMax BML film (Kodak).
Mass spectrometry
Analysis of purified Angptl2-GST by mass spectrometry
was performed by the Proteomics Core facility at the
Institute for Research in Immunology and Cancer in
Montreal, Qc, Canada (http://www.iric.ca/en/research/
core-facilities/proteomics/).
Endotoxin Quantitation
The assessment of endotoxin content of the purified
Angptl2-GST preparations was determined by the Limulus
Amebocyte Lysate (LAL) method using LAL Chromogenic
Endotoxin Qunatitation Kits from Pierce according to the
Manufacturer’s instructions.
Endothelial cell migration assay
To verify the ability of purified recombinant human
Angptl2-GST to function as a chemioattractant, we ex-
amined its ability to stimulate HUVEC migration in 48-
well plates containing polycarbonate transwell inserts
(Neuro Probe Inc., 5 μm pore size) as described previ-
ously (Bernatchez et al. 2003). HUVECs were suspended
in serum-free media at 106 cells/ml and 20 μl of this solu-
tion was plated in the upper chamber. The low chamber
contained 50 μl serum-free media alone or serum-free
media supplemented with either VEGF (25 nM) or
Angptl2-GST (1 nM). Plates were placed in an incubator
at 37°C for 1 h. The cells remaining on the upper surface
of the transwell insert were removed and those cells hav-
ing migrated through to the lower surface were fixed and
stained using the Diff-Quick staining kit (Fisher Scientific).
Inserts were then dried overnight at room temperature
and mounted on microscope slides using a drop of oil.
The number of stained cells having migrated across the
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(40 ×) in 5 separate fields per sample. Each condition was
performed in duplicate.
Microtubule Formation
Human umbilical vein endothelial cells (HUVECs) were
plated at 2 × 105 cells/well into 24- well plates precoated
with Matrigel. After 24 h, the media was replaced with
fresh media containing Angptl2 (1 nM) or VEGF (25
nM). Twenty-four h later, images were acquired using
BTV Pro software and the number of microtubules was
determined in 5 representative fields in each well.
Abbreviations
Angptl2: Angiopoietin-like protein 2; HUVEC: Human umbilical vein
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